FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Medical Devices

Roche Breakthrough Status for Companion Diagnostic

FDA grants Roche a breakthrough device designation for its Elecsys GDF-15 assay as a companion diagnostic in cancer treatment.

Human Drugs

Supernus Resubmits NDA for ADHD Drug

Supernus Pharmaceuticals refiles its NDA for SPN-812 for treating ADHD in pediatric patients.

Human Drugs

FDA Alert on Compounding Remdesivir for Covid

FDA urges drug compounders not to compound drug products using any remdesivir active pharmaceutical ingredient due to its complex nature that makes it...

Human Drugs

Ellodi Pharma Gains Fast Track for Eosinophilic Esophagitis

FDA grants Ellodi Pharmaceuticals a fast track designation for APT-1011 (fluticasone propionate) oral disintegrating tablet for treating eosinophilic ...

Human Drugs

Accelerated Approval for TG Therapeutics Ukoniq

FDA grants TG Therapeutics accelerated approval for Ukoniq (umbralisib), a kinase inhibitor including PI3K-delta and casein kinase CK1-epsilon for tre...

Human Drugs

Topics from GDUFA 3 Reauthorization Meeting

FDA releases a summary of the 12/17/20 GDUFA reauthorization meeting.

FDA General

Woodcock Addresses Covid Variants Impact on Products

FDA Acting commissioner Janet Woodcock says FDA is developing guidances for developers of Covid-19 diagnostics, therapeutics and vaccines to help guid...

Human Drugs

FDA Reviewers Question Keytruda Breast Cancer Study

FDA reviewers take issue with a Merck study supporting a new indication for Keytruda (pembrolizumab) for treating patients with high-risk early-stage ...

Medical Devices

De Novo Granted for Snoring/Sleep Apnea Device

FDA grants a Signifier Medical Technologies de novo request to permit the marketing of a new prescription-only device, eXciteOSA, intended to reduce s...

Biologics

EUA Revised to Limit Convalescent Plasma Use

FDA limits the emergency use authorization for Covid-19 convalescent plasma after evaluating the most recent information available.